Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma
Stopped due to poor response
Conditions
- Blastic Plasmacytoid Dendritic Cell Neoplasm
- Hepatosplenic T-Cell Lymphoma
- HTLV-1 Infection
- NK-Cell Lymphoma, Unclassifiable
- Primary Systemic Anaplastic Large Cell Lymphoma, ALK-Negative
- Recurrent Adult T-Cell Leukemia/Lymphoma
- Recurrent Anaplastic Large Cell Lymphoma
- Recurrent Angioimmunoblastic T-cell Lymphoma
- Recurrent Enteropathy-Associated T-Cell Lymphoma
- Recurrent Mycosis Fungoides
- Refractory Adult T-Cell Leukemia/Lymphoma
- Refractory Anaplastic Large Cell Lymphoma
- Refractory Angioimmunoblastic T-cell Lymphoma
- Refractory Enteropathy-Associated T-Cell Lymphoma
- Refractory Mycosis Fungoides
- Refractory Nasal Type Extranodal NK/T-Cell Lymphoma
- Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified
Interventions
- OTHER: Laboratory Biomarker Analysis
- BIOLOGICAL: Nivolumab
Sponsor
Mayo Clinic
Collaborators